trending Market Intelligence /marketintelligence/en/news-insights/trending/kn0ug6tyg8zqovbsdiocww2 content esgSubNav
In This List

Coherus Biosciences raises $80.8M via common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Coherus Biosciences raises $80.8M via common stock offering

Coherus Biosciences Inc. sold 5,948,274 of its common shares at $14.50 apiece in an underwritten public offering.

The shares sold included the full exercise of the underwriters' option to buy up to an additional 775,861 shares in the offering.

Coherus received net proceeds of about $80.8 million from the sale of the common shares in the offering.

The company plans to use the net proceeds to launch, manufacture and manage the commercial supply of its drug candidate CHS-1701, a biosimilar of Amgen Inc.'s Neulasta. In addition, the proceeds will be used for the ongoing manufacturing, development and clinical trial activities related to CHS-0214, CHS-1420, CHS-3351, CHS-2020 and CHS-131.

Any remaining proceeds from this offering will be used for working capital and other general corporate purposes.

J.P. Morgan and Citigroup served as joint book-running managers for the offering, with Mizuho Securities as lead manager. Baird, Maxim Group LLC and H.C. Wainwright & Co. served as co-managers.

Redwood City, Calif.-based Coherus BioSciences is a biosimilar company, which develops and commercializes various therapeutic products worldwide.